LARGUE PHARMACY LIMITED

Company Registration Number:
SC257732 (Scotland)

Unaudited abridged accounts for the year ended 31 August 2023

Period of accounts

Start date: 01 September 2022

End date: 31 August 2023

LARGUE PHARMACY LIMITED

Contents of the Financial Statements

for the Period Ended 31 August 2023

Balance sheet
Notes

LARGUE PHARMACY LIMITED

Balance sheet

As at 31 August 2023


Notes

2023

2022


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 287,000 349,500
Tangible assets: 4 269,640 206,783
Investments:   0 0
Total fixed assets: 556,640 556,283
Current assets
Stocks: 181,581 164,096
Debtors:   195,801 255,744
Cash at bank and in hand: 565,169 507,136
Investments:   0 0
Total current assets: 942,551 926,976
Creditors: amounts falling due within one year: 5 (400,977) (400,370)
Net current assets (liabilities): 541,574 526,606
Total assets less current liabilities: 1,098,214 1,082,889
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: (24,921) (16,606)
Total net assets (liabilities): 1,073,293 1,066,283
Capital and reserves
Called up share capital: 1,250 1,250
Share premium account: 0 0
Revaluation reserve: 00
Other reserves: 0 0
Profit and loss account: 1,072,043 1,065,033
Shareholders funds: 1,073,293 1,066,283

The notes form part of these financial statements

LARGUE PHARMACY LIMITED

Balance sheet statements

For the year ending 31 August 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 25 March 2024
and signed on behalf of the board by:

Name: Gordon Largue
Status: Director

The notes form part of these financial statements

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2023

2. Employees

2023 2022
Average number of employees during the period 21 20

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2023

3. Intangible Assets

Total
Cost £
At 01 September 2022 1,250,000
Additions 0
Disposals 0
Revaluations 0
Transfers 0
At 31 August 2023 1,250,000
Amortisation
At 01 September 2022 900,500
Charge for year 62,500
On disposals 0
Other adjustments 0
At 31 August 2023 963,000
Net book value
At 31 August 2023 287,000
At 31 August 2022 349,500

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2023

4. Tangible Assets

Total
Cost £
At 01 September 2022 504,646
Additions 97,432
Disposals 0
Revaluations 0
Transfers 0
At 31 August 2023 602,078
Depreciation
At 01 September 2022 297,863
Charge for year 34,575
On disposals 0
Other adjustments 0
At 31 August 2023 332,438
Net book value
At 31 August 2023 269,640
At 31 August 2022 206,783

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2023

5. Creditors: amounts falling due within one year note

Trade creditors £368119Taxation etc £22891Other creditors £9967